Aldeyra Therapeutics (ALDX) said Tuesday that patient-reported ocular discomfort and itching were "statistically lower" with reproxalap compared with...
Aldeyra Therapeutics (ALDX) said Tuesday it completed enrollment in the first part of the phase 3 trial of ADX-2191 in patients with proliferative...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV)...
| Address | 131 Hartwell Avenue Lexington, Massachusetts 02421 |
| Phone | +1.781.761.4904 |
| Number of Employees | 19 |
| Recent SEC Filing | 01/04/2022 SC 13G/A |
| President, Chief Executive Officer & Director | Todd C. Brady |
| Chief Financial Officer | Joshua Reed |
| Vice President & Controller | Bruce Greenberg |
| Senior Vice President-Clinical Development | James A. Gow |
| Price Open | $3.55 |
| Previous Close | $3.42 |
| 52 Week Range | $3.00 - 15.95 |
| Market Capitalization | $198.7 M |
| Shares Outstanding | 58.1 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/10/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.06 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -33.38% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
